For years, the immune system's power to fight cancer has been harnessed in blood cancers but has met a stubborn wall in solid tumors — tumors that hide, resist, and endure. At the Heidelberg Children's Cancer Center, researchers may have found a crack in that wall: a single infusion of reprogrammed T-cells targeting the PRAME protein brought a 17-year-old with widely metastatic Wilms tumor into complete remission, sustained now for over a year. The case, published in the New England Journal of Medicine in August 2026, does not yet rewrite the standard of care — but it asks, with quiet urgency,
Targeted T-cell therapy achieves complete remission in advanced pediatric solid tumor
A 17-year-old patient with widely metastatic cancer who had exhausted conventional treatment options achieved complete remission through experimental T-cell therapy.